Pharma Industry News

Migraine drug bad news hits a weakened Teva

Written by David Miller

The cacophony of bad news that Teva has received in 2017 really needs no retelling, anyone following the story of the company’s struggles already knows most of the details.

One new feature to the company is Teva’s President and CEO, Kåre Shultz, who was tasked with the delivering the full year financial reports. It was an unenviable position to be in, as he revealed the dire straits the company is currently in.

read more

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]